J M Llovet

Summary

Country: Spain

Publications

  1. ncbi The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, IDIBAPS, , University of Barcelona, Catalonia, Spain
    Liver Transpl 10:S115-20. 2004
  2. ncbi Resection and liver transplantation for hepatocellular carcinoma
    Josep M Llovet
    BCLC Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Semin Liver Dis 25:181-200. 2005
  3. ncbi Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    Clin Cancer Res 18:2290-300. 2012
  4. ncbi Hepatocellular carcinoma: present status and future prospects
    Josep M Llovet
    , Liver Unit, , , University of Barcelona, Villarroel, 170, 08036, Catalonia, Barcelona, Spain
    J Hepatol 38:S136-49. 2003
  5. ncbi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
  6. ncbi Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
  7. ncbi Clinical and molecular classification of hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, NY, USA
    Liver Transpl 13:S13-6. 2007
  8. ncbi Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
    Hepatology 37:429-42. 2003
  9. ncbi Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation
    J M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Gut 50:123-8. 2002
  10. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008

Detail Information

Publications83

  1. ncbi The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, IDIBAPS, , University of Barcelona, Catalonia, Spain
    Liver Transpl 10:S115-20. 2004
    ..Finally, patients with end-stage disease should receive only palliative treatment to avoid unnecessary suffering...
  2. ncbi Resection and liver transplantation for hepatocellular carcinoma
    Josep M Llovet
    BCLC Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Semin Liver Dis 25:181-200. 2005
    ..Living donor liver transplantation is having a minor impact in HCC management. Molecular markers are needed to better select the candidates for surgery...
  3. ncbi Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, CIBERehd, Institut d Investigacions Biomédiques, August Pi i Sunyer, Hospital Clinic Barcelona, Barcelona, Spain
    Clin Cancer Res 18:2290-300. 2012
    ..One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy...
  4. ncbi Hepatocellular carcinoma: present status and future prospects
    Josep M Llovet
    , Liver Unit, , , University of Barcelona, Villarroel, 170, 08036, Catalonia, Barcelona, Spain
    J Hepatol 38:S136-49. 2003
  5. ncbi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  6. ncbi Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
    ..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine...
  7. ncbi Clinical and molecular classification of hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Disease, Mount Sinai School of Medicine, NY, USA
    Liver Transpl 13:S13-6. 2007
  8. ncbi Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
    Hepatology 37:429-42. 2003
    ..In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease...
  9. ncbi Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation
    J M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Gut 50:123-8. 2002
    ..Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor...
  10. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  11. ncbi Novel advancements in the management of hepatocellular carcinoma in 2008
    Josep M Llovet
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, CIBERehd, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 48:S20-37. 2008
    ..Now, the research effort faces other areas of unmet need, such as the adjuvant setting of resection/local ablation and combination therapies...
  12. ncbi Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma
    J M Llovet
    Liver Unit, , , University of Barcelona, Catalonia, Spain
    Hepatology 33:1124-9. 2001
    ..Iatrogenic dissemination was related to subcapsular location or an invasive tumoral pattern, and has to be considered when selecting curative treatments for HCC or adjuvant therapies before liver transplantation...
  13. ncbi Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?
    R Vilana
    Diagnosis Imaging Center, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Eur Radiol 16:2454-62. 2006
    ..The 1-month CEUS has a high diagnostic accuracy compared with spiral-CT in the usual assessment of percutaneous treatment response...
  14. ncbi Prognosis of hepatocellular carcinoma
    Josep M Llovet
    Barcelona-Clinic Liver Cancer (BCLC) Group, Liver Unit, Institut de Malalties Digestives, , University of Barcelona, Catalonia, Spain
    Hepatogastroenterology 49:7-11. 2002
    ..In addition to predicting prognosis, the staging system should also guide the selection of treatment and this is the major advantage of the classification applied in the Barcelona-Clinic Liver Cancer Group...
  15. ncbi Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, , , University of Barcelona, Catalonia, Spain
    Hepatology 40:1352-60. 2004
    ..Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function...
  16. ncbi Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials
    P M Lopez
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Aliment Pharmacol Ther 23:1535-47. 2006
    ..Therefore, there is an urgent request to conduct well-designed phase III investigations in hepatocellular carcinoma patients...
  17. ncbi New aspects of diagnosis and therapy of hepatocellular carcinoma
    J Bruix
    BCLC Group, Liver Unit, IDIBAPS, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Oncogene 25:3848-56. 2006
    ..Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression...
  18. ncbi Treatment of hepatocellular carcinoma: is there an optimal strategy?
    Maria Varela
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Villarroel 170, Barcelona, Spain
    Cancer Treat Rev 29:99-104. 2003
    ..Finally, patients with end-stage disease with heavily impaired liver function (Child-Pugh class C) or severe physical impairment (performance status 3-4) die within 6 months and should receive only symptomatic treatment...
  19. ncbi Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?
    Sasan Roayaie
    Division of Liver Diseases and Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Liver Dis 9:315-28. 2005
    ..It is estimated that by the year 2010, the number of patients with HCC awaiting liver transplant in the United States will outnumber the supply of cadaver organs...
  20. ncbi Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation
    Ramon Vilana
    Radiology Department, , , University of Barcelona, Calle Villarroel, 170, 08036 Barcelona, Spain
    J Clin Ultrasound 31:119-28. 2003
    ..However, although contrast-enhanced PDI may be useful for real-time guidance of treatment, its low sensitivity makes it inadequate to accurately assess the completeness of ablation...
  21. ncbi A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
    Gastroenterology 131:1758-67. 2006
    ..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)...
  22. ncbi A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
    J M Llovet
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Eur J Cancer 37:1352-8. 2001
    ..In conclusion, oral eniluracil/5-FU had minimal, if any, activity in patients with inoperable HCC, but the safety profile was acceptable...
  23. ncbi Non-surgical therapies of hepatocellular carcinoma
    Josep M Llovet
    BCLC Group, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Spain
    Eur J Gastroenterol Hepatol 17:505-13. 2005
    ..At more advanced stages, only chemoembolization has been shown to improve survival in well-selected candidates...
  24. ncbi Applicability of adult-to-adult living donor liver transplantation
    Antoni Rimola
    Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 43:104-9. 2005
    ..We report the first data in a European center of the process leading to this procedure from the first moment the patients were informed about it...
  25. ncbi Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
    Alejandro Forner
    BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain
    Hepatology 47:97-104. 2008
    ..These results validate the American Association for the Study of Liver Disease (AASLD) guidelines...
  26. ncbi Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  27. ncbi Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Divisions of Liver Disease and Recanati Miller Transplantation Institute, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Semin Liver Dis 26:248-53. 2006
    ..Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care...
  28. ncbi Pathogenesis of hepatocellular carcinoma and molecular therapies
    Beatriz Minguez
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Curr Opin Gastroenterol 25:186-94. 2009
    ..This review aims to summarize the most relevant genetic alterations and pathways involved in the development and progression of HCC, providing an overview of the molecular targeted therapies tested so far in human HCC...
  29. ncbi Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
    Sigal Kremer Tal
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 46:645-54. 2007
    ..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation...
  30. ncbi Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
    Elisa Wurmbach
    Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:938-47. 2007
    ..CONCLUSION: These findings provide a comprehensive molecular portrait of genomic changes in progressive HCV-related HCC...
  31. ncbi Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers
    Myron Schwartz
    Mount Sinai Liver Cancer Program, Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, New York, NY 10029, USA
    J Hepatol 49:581-8. 2008
    ..This study uses molecular data to identify a subgroup of patients who, despite having hepatocellular carcinoma beyond Milan criteria, have favorable outcomes...
  32. ncbi Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal
    Patricia M Lopez
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, 1425 Madison Avenue, 11F-70, Box 1123, New York, NY 10029, USA
    Liver Transpl 12:1747-54. 2006
  33. ncbi Chemoembolization for hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Gastroenterology 127:S179-88. 2004
    ..The analysis of efficacy in these trials should be adjusted for prognostic factors, such as the presence of symptoms, Child-Pugh class, and segmental vascular invasion...
  34. ncbi Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography
    Juan R Ayuso
    Department of Radiology, Centre de Diagnostic per la Imatge Clinic, Institut Clinic de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August PiI Sunyer, University of Barcelona, Barcelona, Spain
    Liver Transpl 10:1391-7. 2004
    ..002). In conclusion, Mn-DPDP-enhanced MRC is highly accurate in depicting the biliary duct anatomy and can be used preoperatively for surgical planning in LDLT...
  35. ncbi Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy
    Augusto Villanueva
    HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques Agusto Pi i Sunyer IDIBAPS, Liver Unit, Hospital Clinic, Barcelona, Spain
    Annu Rev Med 61:317-28. 2010
    ..Genomic information from tumor and nontumoral tissue will aid prognosis prediction and facilitate the identification of oncogene addiction loops, providing the opportunity for more personalized medicine...
  36. ncbi p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma
    Carolina Armengol
    , Liver Unit, Digestive Disease Institute, , , University of Barcelona, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 38:591-7. 2003
    ..015) and microvascular invasion (P=0.016). CONCLUSIONS: p27 underexpression is frequent in relatively early stages of HCC and constitutes an independent predictor of recurrence after surgical resection...
  37. ncbi Hepatitis B virus and hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Digestive Disease Institute, , IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 39:S59-63. 2003
  38. ncbi Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study
    Josep Fuster
    Department of Surgery, Hospital Clinic, University of Barcelona, Spain
    Hepatogastroenterology 51:536-40. 2004
    ..The objective of our study is to assess the usefulness of intra-abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients...
  39. ncbi Lymphotoxins: new targets for hepatocellular carcinoma
    Augusto Villanueva
    HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Liver Unit Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Hospital Clinic, BCN 08036, Barcelona, Spain
    Cancer Cell 16:272-3. 2009
    ..Aberrant activation of this cascade in mice livers recapitulates the stages of fibrosis and inflammation that precedes human liver cancer, providing a novel family of potential therapeutic targets...
  40. ncbi Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation
    Montserrat Garcia-Retortillo
    Liver Unit, Hospital Clinic, Institut de Malalties Digestives, , Barcelona, Spain
    Hepatology 40:699-707. 2004
    ..Although our results were based on a single-center experience, they should be considered in the decision-making process of transplant programs, since severe HCV recurrence may ultimately compromise graft and patient survival...
  41. ncbi Prognostic assessment and evaluation of the benefits of treatment
    Jordi Bruix
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive, Disease Institute, Barcelona, Catalonia Spain
    J Clin Gastroenterol 35:S138-42. 2002
    ..Finally, those with severe liver function or health status impairment constitute the end-stage category and cannot be expected to survive more than 1 year...
  42. ncbi Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatology 36:986-92. 2002
    ..In conclusion, a combination of easily accessible variables accurately predicts the absence of significant fibrosis and might render liver biopsy unnecessary in more than one third of patients with chronic hepatitis C...
  43. ncbi Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, , University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002
    ..45 [95% CI 0.25-0.81], p=0.02). INTERPRETATION: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma...
  44. ncbi Prognostic prediction and treatment strategy in hepatocellular carcinoma
    Jordi Bruix
    , Liver Unit, Digestive Disease Institute, , Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Hepatology 35:519-24. 2002
  45. ncbi Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma
    M Varela
    , Liver Unit IMD, , , University of Barcelona, Catalonia, Spain
    Aliment Pharmacol Ther 17:98-102. 2003
    ..To achieve both aims, within the Barcelona Clinic Liver Cancer Group we have developed a staging system that combines prognosis prediction with decision making, thus becoming a useful tool both for practice and research...
  46. ncbi High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001
    ..Therefore, a mutated HCV-PKR-bd phenotype is very common in cirrhotic patients with hepatocellular carcinoma...
  47. ncbi Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
    ..The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy...
  48. ncbi Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics
    Maria Varela
    Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
    J Hepatol 46:474-81. 2007
    ..This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity...
  49. ncbi Hepatocellular carcinoma: a clinical update
    Fernando Pons-Renedo
    , Liver Unit, Digestive Disease Institut, , , University of Barcelona, Catalonia, Spain
    MedGenMed 5:11. 2003
  50. ncbi A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma
    Sasan Roayaie
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 137:850-5. 2009
    ..We examined a large cohort of patients with HCC who were treated by resection to identify features of mVI that correlated with recurrence and survival...
  51. ncbi Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound
    Josep M Llovet
    Barcelona-Clinic Liver Cancer (BCLC) Group, Liver Unit, Digestive Disease Institute, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS, , University of Barcelona, Catalonia, Spain
    Clin Gastroenterol Hepatol 4:29-35. 2006
  52. ncbi Updated treatment approach to hepatocellular carcinoma
    Josep M Llovet
    BCLC Group, Liver Unit, Digestive Disease Institute, IDIBAPS, , University of Barcelona, Catalonia, Spain
    J Gastroenterol 40:225-35. 2005
    ..New drugs, such as tyrosine kinase inhibitors and anti-angiogenic agents, are currently being tested in the setting of clinical trials...
  53. ncbi MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation
    Marta Burrel
    Radiology Department, , , University of Barcelona, Catalonia, Spain
    Hepatology 38:1034-42. 2003
    ..In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies...
  54. ncbi High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation
    Margarita Sala
    Liver Unit, , , University of Barcelona, Catalonia, Spain
    Liver Transpl 10:1294-300. 2004
    ..In conclusion, this policy is clinically effective and could further improve the outcome of resected patients...
  55. ncbi Liver transplantation in hepatocellular carcinoma
    Josep Fuster
    Barcelona-Clinic Liver Cancer (BCLC) Group, Department of Surgery, Digestive Disease Institute, , Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Transpl Int 18:278-82. 2005
    ..The development of adult living donor liver transplantation has proved to be a good alternative in this type of patients even if they do not fulfill the conventional criteria...
  56. ncbi Molecular approaches to treatment of hepatocellular carcinoma
    Anja Lachenmayer
    Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
    Dig Liver Dis 42:S264-72. 2010
    ..In this article we review the current knowledge of the molecular pathogenesis of HCC and provide an overview of molecular targeted therapies in the management of HCC...
  57. ncbi [Adult living donor liver transplantation. Analysis of the first 30 cases]
    J C Garcia-Valdecasas
    Sección de Cirugía Hepática y Trasplante, Institut de Malalties Digestives, Hospital Clinic, Universidad de Barcelona, Barcelona, Espana
    Gastroenterol Hepatol 26:525-30. 2003
    ..Despite this, analysis of the results is still incomplete. The aim of the present study was to perform a descriptive analysis of the results after the first 3 years of the initiation of the program...
  58. ncbi Genomics and signaling pathways in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 27:55-76. 2007
    ..This review summarizes the most relevant information regarding structural and functional alterations in HCC and describes some of the key signaling pathways implicated in hepatocarcinogenesis...
  59. ncbi Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps
    Augusto Villanueva
    BCLC Group, Liver Unit, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Curr Opin Oncol 20:444-53. 2008
    ....
  60. ncbi Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling
    Eric R Lemmer
    Mount Sinai Liver Cancer Program, Division of Liver Disease, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 26:373-84. 2006
    ..Continued progress is anticipated in the practical application of gene array methods to refine diagnosis and therapy of HCC...
  61. ncbi Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma
    Steven Yea
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Gastroenterology 134:1521-31. 2008
    ..The molecular basis for stimulation of KLF6 splicing is unknown...
  62. ncbi IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
    Victoria Tovar
    HCC Translational Laboratory, BCLC Group, Liver Unit and Pathology Department, Hospital Clinic, CIBERehd, IDIBAPS, C Villarroel 170, Catalonia, Spain
    J Hepatol 52:550-9. 2010
    ..We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma (HCC; BCLC class 0 or A) and assessed novel targeted therapies blocking this pathway...
  63. ncbi Evidence-based medicine in the treatment of hepatocellular carcinoma
    Josep M Llovet
    , Liver Unit, , , University of Barcelona, Catalonia, Spain
    J Gastroenterol Hepatol 17:S428-33. 2002
    ..A recent randomized trial reported that chemoembolization may benefit HCC patients in terms of survival, but additional studies to confirm this data are recommended...
  64. ncbi Hepatocellular carcinoma
    Josep M Llovet
    , Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli;nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Lancet 362:1907-17. 2003
    ..Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC...
  65. ncbi Pivotal role of mTOR signaling in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 135:1972-83, 1983.e1-11. 2008
    ..We evaluated mTOR signaling in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR pathway...
  66. ncbi Approaching focal liver lesions
    F Pons
    Liver Oncology, Service of Hepatology, IDIBAPS, , Barcelona, Spain
    Rev Esp Enferm Dig 96:567-73; 573-7. 2004
  67. ncbi Focus on hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Cancer Cell 5:215-9. 2004
  68. ncbi Expected developments in hepatology
    Xavier Forns
    Liver Unit, , , University of Barcelona, Spain
    Best Pract Res Clin Gastroenterol 16:957-70. 2002
    ..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies...
  69. ncbi [Cell biology and genetics in liver cancer]
    Victoria Tovar
    BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, Barcelona, Espana
    Gastroenterol Hepatol 30:360-9. 2007
    ..This review summarizes the most important information on the structural and functional alterations in HCC and describes some of the main signaling pathways implicated in liver cancer...
  70. ncbi Experimental models of hepatocellular carcinoma
    Philippa Newell
    Division of Liver Diseases, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 48:858-79. 2008
    ..These models will be instrumental in the evaluation of compounds targeting specific molecular pathways in future preclinical studies...
  71. ncbi Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma
    Josep M Llovet
    J Natl Cancer Inst 100:1121-3. 2008
  72. ncbi HCC surveillance: who is the target population?
    Jordi Bruix
    Hepatology 37:507-9. 2003
  73. ncbi Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision
    Jordi Bruix
    Liver Transpl 9:700-2. 2003
  74. ncbi Gene expression profiles in hepatocellular carcinoma: not yet there
    Josep M Llovet
    J Hepatol 41:336-9. 2004
  75. ncbi Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing
    Giovanna Fattovich
    J Hepatol 44:1013-6. 2006
  76. ncbi Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis
    Vincenzo Mazzaferro
    Department of Surgery, Biomedical Statistics, Pathology, National Cancer Institute of Milan and Chair of Gastroenterology, Policlinico Foundation, Department of Medicine, University of Milan, Italy
    Hepatology 44:1543-54. 2006
    ..3; 95% CI: 0.09-0.9; P = .04). In conclusion, IFN does not affect overall prevention of HCC recurrence after resection, but it may reduce late recurrence in HCV-pure patients receiving effective treatment...
  77. ncbi Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data
    Josep M Llovet
    Liver Transpl 12:1741-3. 2006
  78. ncbi Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
    Norbert Brau
    Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    J Hepatol 47:527-37. 2007
    ..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
  79. ncbi Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?
    Riccardo Lencioni
    J Hepatol 43:377-80. 2005
  80. ncbi Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials
    Pippa Newell
    J Hepatol 49:1-5. 2008
  81. ncbi Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
    Derek Y Chiang
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:6779-88. 2008
    ..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies...
  82. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
    ..In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed...
  83. ncbi Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization
    Josep M Llovet
    Radiology 230:300-1; author reply 301-2. 2004